URGN Stock Price, Chart, Stats & News
UroGen Pharma Ltd. (URGN) does not currently pay a dividend.
URGN chart
Fundamentals
Gross margin | 88.66% |
Operating margin | -113.73% |
Pretax margin | -139.74% |
Net margin | -139.81% |
Effective tax rate | -0.05% |
ROA | -76.57% |
ROE | 170.21% |
D/E | -1.22x |
Interest coverage ratio | -3.69x |
URGN valuation
P/E | – |
P/S | 7.61x |
P/B | -8.01x |
P/CF | -5.20x |
P/FCF | -5.14x |
P/OCF | -5.20x |
PEG | -0.73x |
EV multiple | -6.03x |
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC.
Similar securities
Based on sector and market capitalization
